# US 8,278,424 B2 · Antibodies that bind to PSCA proteins for diagnosis of cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,278,424 B2
- Document ID: US8278424B2
- Status: Granted
- Kind: B2
- Application number: 13/094,730
- Filed: 2011-04-26
- Published: 2011-10-27
- Granted: 2012-10-02
- Earliest claimed: 2003-05-30
- Assignees: Agensys, Inc.
- Inventors: Jean Gudas; Aya Jakobovits; Xiao-chi Jia; Robert Kendall Morrison; Karen Jane Meyrick Morrison; Hui Shao; Pia M. Challita-Eid; Arthur B. Raitano
- Web page: https://patentgrep.com/patent/US8278424B2

## CPC

- C07K 14/4748: {Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE}
- A61K 39/0011: {Cancer antigens}
- A61K 40/19: Dendritic cells
- A61K 40/24: Antigen-presenting cells [APC]
- A61K 40/4275: {Prostate specific antigen [PSA]}
- A61K 51/1051: {the tumor cell being from breast, e.g. the antibody being herceptin}
- A61K 51/1054: {the tumor cell being from lung}
- A61K 51/1057: {the tumor cell being from liver or pancreas}
- A61K 51/106: {the tumor cell being from kidney or bladder}
- A61K 51/1072: {the tumor cell being from the reproductive system, e.g. ovaria, uterus, testes or prostate}
- A61P 35/00: Antineoplastic agents
- A61P 39/00: General protective or antinoxious agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 14/705: Receptors; Cell surface antigens; Cell surface determinants {(tumour specific antigens C07K14/4748)}
- C07K 16/30: from tumour cells
- C07K 16/3069: {Reproductive system, e.g. ovaria, uterus, testes, prostate}
- G01N 33/566: using specific carrier or receptor proteins as ligand binding reagents {where possible specific carrier or receptor proteins are classified with their target compounds}
- G01N 33/57515: of the breast
- A61K 2039/53: {DNA (RNA) vaccination}
- A61K 2239/58: Prostate
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Antibodies and molecules derived therefrom that bind to novel PSCA protein, and variants thereof, are described wherein PSCA exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, PSCA provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The PSCA gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with PSCA can be used in active or passive immunization.

## Claims

### Claim 1

A monoclonal antibody or antigen binding fragment thereof comprising an antigen binding site that binds specifically to a PSCA protein comprising the amino acid sequence of SEQ ID NO:2, and wherein the monoclonal antibody comprises the amino acid sequence of the VH region and the VL region produced by the hybridoma deposited under American Type Culture Collection (ATCC) Accession No. PTA-6699.

### Claim 2 (depends on 1)

The antibody or fragment of claim 1, wherein the fragment is an Fab, F(ab′)2, Fv or scFv fragment.

### Claim 3 (depends on 1)

The antibody or fragment of claim 1, wherein the antibody or fragment is coupled to a detectable marker.

### Claim 4 (depends on 1)

A hybridoma that produces the monoclonal antibody of claim 1.

### Claim 5 (depends on 4)

The hybridoma of claim 4, wherein the hybridoma is deposited under American Type Culture Collection (ATCC) Accession No. PTA-6699.

### Claim 6 (depends on 1)

A polynucleotide that encodes a sequence comprising the light chain variable region and the heavy chain variable region of the antibody of claim 1.

### Claim 7 (depends on 6)

The polynucleotide of claim 6, wherein the light chain is encoded by SEQ ID NO: 36 and the heavy chain is encoded by SEQ ID NO: 34.

### Claim 8 (depends on 7)

A vector comprising the polynucleotide of claim 7.

### Claim 9 (depends on 8)

An isolated cell transfected with the vector of claim 8.

### Claim 10 (depends on 1)

A method of producing an antibody as defined in claim 1 or an antigen binding fragment thereof, comprising: culturing a cell, wherein: (a) the cell has been transfected with a vector comprising a polynucleotide that encodes a sequence comprising the light chain variable region of the antibody of claim 1 and a vector comprising a polynucleotide that encodes a sequence comprising the heavy chain variable region of the antibody of claim 1; whereby the antibody or an antigen binding fragment thereof is produced.

### Claim 11 (depends on 1)

A method for detecting a PSCA protein comprising the amino acid sequence of SEQ ID NO:2 in a biological sample, comprising steps of: providing the biological sample and a control sample; contacting the biological sample and the control sample with the antibody of claim 1, that specifically binds to the PSCA protein, wherein the protein comprises the amino acid sequence of SEQ ID NO:2; and determining an amount of a complex of the substance with the PSCA protein comprising the amino acid sequence of SEQ ID NO:2 and the antibody present in the biological sample and the control sample.

### Claim 12 (depends on 11)

The method of claim 11 further comprising: taking the biological sample and the control sample from a patient who has or is suspected of having a cancer selected from the group consisting of prostate, pancreas, bladder, kidney, colon, lung, ovary, and breast cancer.

### Claim 13 (depends on 12)

The method of claim 12, wherein the cancer is prostate, pancreatic, or bladder cancer.

### Claim 14 (depends on 1)

An assay for detecting the presence of a PSCA protein comprising the amino acid sequence of SEQ ID NO:2 in a biological sample comprising contacting the sample with the monoclonal antibody of claim 1, and detecting the binding of the PSCA protein in the sample, wherein the protein comprises the amino acid sequence of SEQ ID NO:2.

### Claim 15 (depends on 14)

The assay of claim 14, wherein the antibody is labeled with a detectable marker.

### Claim 16 (depends on 15)

The assay of claim 15, wherein the biological sample is prostate, pancreatic, or bladder tissue.

### Claim 17 (depends on 1)

A composition comprising the antibody, or antigen binding fragment thereof of claim 1.

### Claim 18 (depends on 17)

The composition of claim 17, wherein the antigen binding fragment is a Fab, a F(ab′)2, a Fv or a sFv fragment.
